Prostate Cancer Life Expectancy: What the Numbers Really Mean

By Mr Neil Haldar, Consultant Urological Surgeon

In brief

Most men diagnosed with prostate cancer—particularly cancer that is still confined to the prostate—have a good long-term outlook.

However, no survival statistic or online calculator can tell an individual man exactly how long he will live.

A meaningful assessment must answer two separate questions:

1. How long is the man likely to live based on his age and general health?
2. How likely is his particular prostate cancer to shorten his life?

The likely benefit of treatment depends on how those two estimates interact. A potentially aggressive cancer in an otherwise healthy man may require active treatment. A small, slow-growing cancer in an older or less healthy man may never cause symptoms or affect life expectancy.

This is why decisions about prostate cancer should be based on the individual—not on a single percentage or headline survival figure.

---

“How long have I got?”

When a man is told that he has prostate cancer, this is often the first question that comes to mind.

It is entirely understandable. However, prostate cancer is more difficult than many other cancers to describe with one life-expectancy figure.

Some prostate cancers grow slowly and may never cause harm. Others are more aggressive and need prompt treatment. Even among men who appear to have similar cancers, their overall outlook may differ because of their age, fitness, other medical conditions and response to treatment.

A newly diagnosed man may therefore be told that his outlook is excellent, that his cancer is unlikely to affect his natural lifespan, or that treatment is recommended to reduce a meaningful long-term risk. These statements can all be appropriate in different circumstances.

The aim of a specialist consultation is not to produce a falsely precise expiry date. It is to explain:

• how serious the cancer appears to be;
• whether it is likely to grow or spread;
• whether it is likely to shorten life;
• how much treatment may reduce that risk;
• what side effects treatment may cause;
• and how certain—or uncertain—those estimates are.

---

Can you live a long life with prostate cancer?

Yes. Many men live for many years or decades after a prostate cancer diagnosis.

This is particularly true when the cancer is:

• confined to the prostate;
• low grade;
• detected before it has caused symptoms;
• growing slowly;
• or responding well to treatment.

Some men with low-risk prostate cancer do not need immediate treatment at all. Instead, they are monitored using active surveillance, which may include PSA tests, MRI scans, clinical reviews and, when necessary, repeat biopsies.

Even when prostate cancer has spread beyond the prostate, modern combinations of hormone treatment, chemotherapy, radiotherapy and newer targeted treatments have substantially improved survival. Some men with advanced prostate cancer live for many years while maintaining a good quality of life.

The outlook therefore depends on much more than the words “prostate cancer” alone.

---

Why general survival statistics can be misleading

You may see statements such as:

• “Nearly all men with localised prostate cancer survive for five years.”
• “Most men with prostate cancer survive for ten years.”
• “Prostate cancer has a survival rate of almost 100% when caught early.”

These figures can be reassuring, but they do not predict what will happen to a particular individual.

There are several reasons for this.

Survival figures include many different cancers

Prostate cancer ranges from tiny, low-grade tumours that may never require treatment to aggressive cancers that have already spread to the bones or other organs.

An average figure combines all these different situations. It cannot describe one man’s cancer without knowing its stage, grade and other characteristics.

Survival figures may not mean what patients assume

Many published cancer statistics describe relative survival. This compares men with prostate cancer with similar men in the general population.

Relative survival is useful for researchers and healthcare systems, but it does not directly tell a 75-year-old man with heart disease or diabetes how likely he is to be alive in ten years.

Earlier diagnosis can make survival appear longer

PSA testing can detect prostate cancer many years before it would otherwise have been found.

A man diagnosed at 60 may appear to have survived ten years longer than a man diagnosed at 70, even if the cancer follows exactly the same biological course. This is known as lead-time bias.

Tests and treatments have changed

Modern MRI, targeted biopsy and PSMA PET-CT scans can identify cancer more accurately than older investigations.

Treatments have also improved. Survival figures based on men diagnosed 15 or 20 years ago may not fully reflect the outlook for a man treated today.

Population figures are therefore useful as background information, but they should never replace an individual assessment.

---

The two parts of a meaningful prognosis

A sensible discussion about prostate cancer life expectancy must consider two risks in parallel.

1. Life expectancy without prostate cancer

Doctors first consider how long the man might otherwise be expected to live.

This is influenced by:

• age;
• heart and lung health;
• diabetes;
• kidney function;
• previous strokes;
• smoking;
• weight;
• mobility;
• independence;
• frailty;
• and general fitness.

Age is important, but it is not enough on its own.

A fit and active man of 78 may have a considerably longer life expectancy than a frail man of 68 with serious heart, lung or neurological disease.

National life tables provide a useful starting point, but they describe population averages. They cannot account for an individual’s health, lifestyle, and fitness.

2. The risk posed by prostate cancer

Doctors then estimate how likely the cancer is to grow, spread, cause symptoms or shorten life.

This depends on factors including:

• the cancer’s Grade Group or Gleason score;
• the PSA level;
• the clinical stage;
• how much cancer was found in the biopsy;
• whether scans show cancer outside the prostate;
• whether lymph nodes or bones are involved;
• and, in some cases, molecular or genetic test results.

Treatment is most likely to produce a meaningful survival benefit when a man has both:

• a sufficiently long natural life expectancy; and
• a prostate cancer that presents a significant future risk.

---

What factors affect prostate cancer life expectancy?

The stage of the cancer

The stage describes where the cancer is located.

Localised prostate cancer

Localised prostate cancer is confined to the prostate.

The long-term outlook is generally excellent, particularly for low-grade and favourable intermediate-risk disease. Some men can safely be monitored, while others benefit from surgery or radiotherapy.

Locally advanced prostate cancer

Locally advanced cancer has grown through the outer edge of the prostate or into nearby structures such as the seminal vesicles.

It carries a greater risk of recurrence or future spread, but it can still often be treated with curative intent. Treatment may involve surgery, radiotherapy, hormone treatment or a combination.

Node-positive prostate cancer

Cancer found in the pelvic lymph nodes has moved beyond the prostate but may still be controlled for many years.

Treatment is increasingly individualised and may include radiotherapy to the prostate and lymph nodes, hormone therapy, surgery in selected circumstances and additional systemic treatment.

Metastatic prostate cancer

Metastatic prostate cancer has spread to distant parts of the body, most commonly the bones or distant lymph nodes.

It is generally treated as a long-term condition rather than with an expectation of cure. However, its behaviour varies greatly. Some cancers respond to treatment for many years, while others are more aggressive.

The number and location of metastases, whether the cancer was metastatic at diagnosis, general health and response to treatment all influence the outlook.

---

The Gleason score and Grade Group

When a pathologist examines prostate tissue under a microscope, they assess how abnormal the cancer cells look.

This is reported as a Gleason score and, increasingly, as a Grade Group:

Grade Group	Typical Gleason score	General interpretation
Grade Group 1	Gleason 3+3=6	Usually slow-growing
Grade Group 2	Gleason 3+4=7	Mostly lower-grade cancer with some higher-grade cells
Grade Group 3	Gleason 4+3=7	More higher-grade cancer and a greater risk than 3+4
Grade Group 4	Gleason 8	High-grade cancer
Grade Group 5	Gleason 9–10	Very high-grade cancer

This distinction matters.

Gleason 3+4 and Gleason 4+3 both add up to seven, but they do not carry the same risk. A 4+3 cancer contains more of the aggressive pattern and generally has a less favourable outlook than a 3+4 cancer.

Grade is important, but it should never be interpreted in isolation. A small Grade Group 2 tumour confined to the prostate is very different from extensive Grade Group 5 disease that has spread to the bones.

---

The PSA level

PSA is a protein produced by prostate tissue. A raised PSA can occur because of prostate cancer, but it can also be caused by:

• benign prostate enlargement;
• prostatitis or infection;
• urinary retention;
• recent prostate procedures;
• and other non-cancerous conditions.

Once prostate cancer has been diagnosed, PSA contributes to risk assessment.

However, the PSA number alone cannot predict life expectancy. Doctors interpret it alongside:

• prostate size;
• PSA density;
• the rate at which PSA is changing;
• MRI findings;
• biopsy results;
• stage;
• and treatment history.

A high PSA does not automatically mean a poor outcome, and a relatively low PSA does not completely exclude aggressive disease.

---

The amount of cancer present

Cancer volume can influence risk.

Doctors may consider:

• how many biopsy samples contain cancer;
• the percentage of each sample affected;
• whether the cancer is present on one or both sides of the prostate;
• the size of visible MRI lesions;
• and whether there is evidence of disease outside the prostate.

A very small amount of favourable disease may be suitable for active surveillance. More extensive cancer, even within the same Grade Group, may require a different approach.

---

Age, general health and fitness

The same prostate cancer can have very different implications for two different men.

For example, a healthy 60-year-old with a potentially aggressive cancer may have many years in which that cancer could progress. He may therefore gain a substantial long-term benefit from treatment.

An 85-year-old with a small, low-grade cancer and serious heart disease may be much more likely to experience harm from treatment than benefit from it.

This does not mean that treatment should be denied because of age. Chronological age should not be used as the sole deciding factor.

A fit older man may be an excellent candidate for treatment. Conversely, a younger man with significant frailty or severe medical problems may need a more conservative approach.

The important question is not simply, “How old is he?” It is, “How healthy and functionally independent is he, and how many years is he realistically likely to live?”

---

The Cambridge Prognostic Groups

In the UK, prostate cancer is often placed into one of five Cambridge Prognostic Groups, usually shortened to CPG.

These groups combine the PSA, Grade Group and clinical stage to provide a more meaningful estimate of prostate-cancer risk.

Group	Broad description
CPG1	Low-grade cancer, PSA below 10 and disease confined to the prostate
CPG2	Favourable intermediate-risk features
CPG3	Less favourable intermediate-risk disease
CPG4	One major high-risk feature, such as a high PSA, high grade or disease extending beyond the prostate
CPG5	Multiple high-risk features, very high-grade disease or more locally advanced cancer

The CPG system is more useful than simply labelling cancers as low-, intermediate-, or high-risk.

For example, CPG2 and CPG3 cancers were previously grouped together as “intermediate risk,” despite having meaningfully different outlooks. Similarly, CPG4 and CPG5 cancers should not be regarded as identical.

Patients should not try to calculate their own CPG from a single test result. The specialist team should confirm the group using complete clinical information.

---

What is PREDICT Prostate?

PREDICT Prostate is a UK-developed online prognostic tool designed to support treatment discussions for men with non-metastatic prostate cancer.

It uses information such as:

• age;
• PSA;
• Grade Group;
• clinical stage;
• biopsy findings;
• and general health.

It can estimate:

• overall survival over the next 10 or 15 years;
• the likelihood of dying from prostate cancer;
• the likelihood of dying from another cause;
• and the possible additional survival benefit from radical treatment.

The last of these is particularly important.

A treatment may significantly reduce the relative risk of dying from prostate cancer while producing only a small change in absolute survival.

For example, reducing a cancer-related risk from 2% to 1% represents a 50% relative reduction, but only a 1% absolute benefit. That means one additional man in every hundred may benefit, while all treated men remain exposed to potential side effects.

PREDICT Prostate helps place these figures in context. It should be used as part of a specialist consultation rather than treated as a precise forecast.

---

Why treatment does not always increase life expectancy

It is natural to assume that removing or irradiating a cancer must always help someone live longer.

That is not necessarily true.

Some prostate cancers grow so slowly that they would not become dangerous during the man’s natural lifetime. Treating these cancers may not add meaningful years of life, but it can still cause side effects such as:

• urinary incontinence;
• erectile dysfunction;
• bowel symptoms;
• urinary irritation;
• tiredness;
• hot flushes;
• reduced libido;
• loss of muscle and bone strength;
• and cardiovascular or metabolic effects.

This is why active surveillance is an established treatment strategy rather than “doing nothing.”

The aim is to avoid or delay unnecessary treatment while retaining the opportunity to treat the cancer if tests suggest that it is becoming more significant.

---

What did the ProtecT trial show?

The UK ProtecT trial compared active monitoring, prostate surgery and radiotherapy in men with PSA-detected localised prostate cancer.

After 15 years, approximately 97% of men had not died from prostate cancer, regardless of which of the three initial approaches they received.

However, there were differences between the groups:

• cancer progression and metastases were more frequent with active monitoring;
• surgery and radiotherapy caused different patterns of urinary, sexual and bowel side effects;
• and many more men died from causes other than prostate cancer than from the cancer itself.

These results are reassuring, but they should be interpreted carefully.

Most participants had lower-risk or intermediate-risk cancer, and the active-monitoring protocol was less intensive than modern MRI-led active surveillance. The findings should not be applied directly to men with very high-risk, node-positive or metastatic disease.

---

How does treatment affect prognosis?

Surgery

Radical prostatectomy removes the prostate and seminal vesicles and may include removal of pelvic lymph nodes.

It provides both treatment and detailed pathological information. Examination of the removed prostate can show:

• the final Grade Group;
• whether the cancer was confined to the prostate;
• whether it had grown through the capsule;
• whether the seminal vesicles were involved;
• whether lymph nodes contained cancer;
• and whether cancer reached a surgical margin.

This information often provides a more accurate estimate of prognosis than was possible before surgery.

The postoperative PSA is also important. It would normally be expected to fall to a very low or undetectable level.

Radiotherapy

Radiotherapy can be highly effective for localised and locally advanced disease.

It may be given alone or with hormone therapy, depending on the cancer’s risk group. In some higher-risk cancers, additional systemic treatment may also be considered.

After radiotherapy, the PSA usually falls gradually rather than becoming immediately undetectable. The lowest PSA reached, the time taken to reach it and any subsequent rise can all provide prognostic information.

Hormone treatment

Androgen-deprivation therapy reduces testosterone, which prostate cancer cells usually depend on for growth.

It may be used:

• alongside radiotherapy;
• after recurrence;
• for node-positive disease;
• or as the foundation of treatment for metastatic prostate cancer.

For advanced disease, hormone therapy is now commonly combined with other treatments because combination therapy can control cancer for longer and improve survival.

---

What is the outlook for metastatic prostate cancer?

There is no single life-expectancy figure for metastatic prostate cancer.

The outlook is influenced by:

• whether the cancer was metastatic when first diagnosed;
• whether it returned after previous surgery or radiotherapy;
• the number and location of metastases;
• whether internal organs are involved;
• the man’s fitness and other health conditions;
• the PSA response to treatment;
• and how long the cancer remains sensitive to hormone therapy.

Men with a small number of metastases may have a different outlook from those with extensive bone or organ involvement.

Modern treatment may include combinations of:

• androgen-deprivation therapy;
• newer hormonal medicines;
• chemotherapy;
• prostate radiotherapy in selected men;
• targeted radiotherapy;
• PARP inhibitors for certain genetic alterations;
• radioligand therapy;
• bone-protecting treatment;
• and clinical trials.

Although metastatic prostate cancer is usually not considered curable, it is often treatable for a substantial period. Some men respond extremely well and live for many years.

---

Prognosis can improve over time

A prognosis is not fixed on the day of diagnosis.

A man who remains well and responds to treatment for several years has already passed through part of the original period of risk. His future outlook may therefore be better than the statistics quoted at diagnosis suggested.

This is sometimes called conditional survival.

For example, a man with advanced cancer who has:

• responded strongly to treatment;
• maintained a low PSA;
• developed no new disease on scans;
• and remained physically well,

has a more favourable outlook than a newly diagnosed man with apparently similar disease.

Prognosis should therefore be reviewed over time rather than treated as a permanent label.

---

Can genomic or artificial intelligence tests improve prediction?

Traditional risk assessment uses PSA, stage, Grade Group, biopsy findings and scans.

In selected cases, additional tests may examine gene activity within the tumour. Examples include Decipher, Prolaris and the Oncotype DX Genomic Prostate Score.

These tests may help identify biological differences between cancers that otherwise appear similar under the microscope.

Artificial-intelligence systems are also being developed to analyse digital biopsy images alongside clinical information. These tools may eventually help predict:

• the likelihood of spread;
• the risk of dying from prostate cancer;
• and whether a man is likely to benefit from a particular treatment.

However, these tests are not required for every patient. Availability and funding in the UK remain limited, and a test is only useful when its result could realistically change the treatment decision.

They should support—not replace—assessment by an experienced multidisciplinary team.

---

How accurate are prostate cancer survival calculators?

Prognostic calculators can be helpful, but they have limitations.

They are based on groups of previous patients. They cannot know exactly what will happen to one individual.

Their predictions may also be affected by:

• when the model was developed;
• which treatments were available at the time;
• whether patients had modern MRI or PSMA PET-CT staging;
• the type of patients included;
• and the outcome the model was designed to predict.

Some calculators estimate PSA recurrence rather than survival. A risk of biochemical recurrence is not the same as a risk of dying from prostate cancer.

A man can experience a rise in PSA after treatment and still live for many years, sometimes without ever developing symptoms from the cancer.

Always check what question the calculator is actually answering.

---

Why doctors should discuss absolute benefit

Treatment results are often presented as relative risk reductions.

For example:

“This treatment reduces the risk by 50%.”

That sounds dramatic, but the meaning depends on the starting risk.

• Reducing a risk from 40% to 20% produces a 20% absolute benefit.
• Reducing a risk from 2% to 1% produces a 1% absolute benefit.

Both represent a 50% relative reduction, but the implications differ greatly.

When discussing treatment, patients should ask:

“Out of 100 men like me, how many are expected to benefit?”

This converts an abstract percentage into a more understandable natural frequency.

---

Questions to ask your urologist

A useful prostate cancer consultation should help you understand:

1. What is my Grade Group and Gleason score?
2. What is the clinical stage?
3. What is my Cambridge Prognostic Group?
4. Has the cancer spread outside the prostate?
5. What is my estimated risk of prostate cancer progression?
6. What is my estimated risk of dying from prostate cancer?
7. How does my general health affect those estimates?
8. What absolute survival benefit might treatment provide?
9. What side effects could treatment cause?
10. Is active surveillance a safe option?
11. Would a second prognostic model or genomic test change the decision?
12. How will my prognosis be reviewed after treatment or during surveillance?

It is reasonable to ask for figures to be explained as ranges rather than exact percentages.

---

Frequently asked questions

---

The most important message

You can’t understand prostate cancer life expectancy from one statistic.

The meaningful questions are:

• How long is this man otherwise likely to live?
• How likely is this particular cancer to shorten his life?
• How much would treatment reduce that risk?
• What harm might treatment cause?
• How certain are the estimates?

For many men with localised prostate cancer, the long-term outlook is excellent. For others, treatment can meaningfully reduce the risk of progression, metastasis and death.

The best decisions combine modern imaging, accurate pathology, validated prognostic tools, general-health assessment, and the individual patient’s priorities.

The aim is not simply to treat a PSA result or remove a prostate. It is to choose the approach most likely to help the man live longer—and live well.

---

Selected references

1. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine. 2023.
2. Gnanapragasam VJ, Bratt O, Muir K, et al. Cambridge Prognostic Groups for prediction of prostate cancer mortality. BMC Medicine. 2018.
3. Thurtle DR, Greenberg DC, Lee LS, et al. Development and validation of the PREDICT Prostate model. PLOS Medicine. 2019.
4. National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. NICE guideline NG131.
5. Cancer Research UK. Prostate cancer survival statistics.

---

This article is intended for general information and does not replace individual medical advice. A specialist should interpret prognostic estimates after reviewing the complete medical history, pathology, and imaging.

Worried About What a Prostate Cancer Diagnosis Means for You?

Prostate cancer can behave very differently from one man to another. Your outlook depends on factors such as the stage of the cancer, Gleason score/Grade Group, PSA level, MRI and biopsy findings, your age and general health, and how the cancer responds to treatment.

If you have recently been diagnosed with prostate cancer—or are trying to understand what your results mean—I offer private consultations and second opinions to help you understand your individual situation and the treatment options available.

I can review your PSA history, MRI scans, biopsy results and staging investigations, explain your likely prognosis in clear terms, and discuss whether active surveillance, surgery, radiotherapy or another approach may be appropriate.

You can also learn more about my prostate cancer service, robotic radical prostatectomy and clinic locations.